139 related articles for article (PubMed ID: 33640159)
1. NKX3.1 immunohistochemistry is highly specific for the diagnosis of mesenchymal chondrosarcomas: experience in the Australian population.
Ramanayake N; Vargas AC; Talbot J; Bonar F; Wong DD; Wong D; Mahar A; Karim R; Luk PP; Selinger C; Sioson L; Gill AJ; Maclean F
Pathology; 2021 Oct; 53(6):705-712. PubMed ID: 33640159
[TBL] [Abstract][Full Text] [Related]
2. NKX3.1 immunoreactivity is not identified in mesenchymal chondrosarcoma: a 25-case cohort study.
Chen W; Hornick JL; Fletcher CDM
Histopathology; 2021 Jan; 78(2):334-337. PubMed ID: 32779239
[TBL] [Abstract][Full Text] [Related]
3. NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study.
Syed M; Mushtaq S; Loya A; Hassan U
Ann Diagn Pathol; 2021 Feb; 50():151660. PubMed ID: 33302222
[TBL] [Abstract][Full Text] [Related]
4. NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.
Yoshida KI; Machado I; Motoi T; Parafioriti A; Lacambra M; Ichikawa H; Kawai A; Antonescu CR; Yoshida A
Am J Surg Pathol; 2020 Jun; 44(6):719-728. PubMed ID: 31972596
[TBL] [Abstract][Full Text] [Related]
5. OLIG2 Immunolabeling of Mesenchymal Chondrosarcoma: Report of 14 Cases.
Yao K; Duan Z; Yang S; Du Z; Wang Y; Qi X
J Neuropathol Exp Neurol; 2020 Sep; 79(9):959-965. PubMed ID: 32770197
[TBL] [Abstract][Full Text] [Related]
6. NKX3.1 immunohistochemistry and methylome profiling in mesenchymal chondrosarcoma: additional diagnostic value for a well-defined disease?
Glauser S; Ameline B; Andrei V; Harder D; Pauli C; Trautmann M; Hartmann W; Baumhoer D
Pathology; 2023 Aug; 55(5):621-628. PubMed ID: 37225644
[TBL] [Abstract][Full Text] [Related]
7. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of NKX 3.1 and HOXB 13 in bone metastases originating from prostatic carcinoma among the Egyptian males.
Abouhashem NS; Salah S
Pathol Res Pract; 2020 Oct; 216(10):153221. PubMed ID: 32979741
[TBL] [Abstract][Full Text] [Related]
9. [Expression and diagnostic value of NKX3.1 and NKX2.2 in mesenchymal chondrosarcoma].
Wang XX; Chen H; Wang X; Ma L; Cheng K; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):114-119. PubMed ID: 35152629
[No Abstract] [Full Text] [Related]
10. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data.
Wang L; Motoi T; Khanin R; Olshen A; Mertens F; Bridge J; Dal Cin P; Antonescu CR; Singer S; Hameed M; Bovee JV; Hogendoorn PC; Socci N; Ladanyi M
Genes Chromosomes Cancer; 2012 Feb; 51(2):127-39. PubMed ID: 22034177
[TBL] [Abstract][Full Text] [Related]
12. Utility of NKX3.1 immunohistochemistry in the differential diagnosis of seminal vesicles versus prostatic tissue in needle biopsy.
Pitra T; Pivovarcikova K; Alaghehbandan R; Compérat EM; Hora M; Rogala J; Slisarenko M; Michal M; Hes O
Ann Diagn Pathol; 2020 Dec; 49():151644. PubMed ID: 33126153
[TBL] [Abstract][Full Text] [Related]
13. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
Jia L; Jiang Y; Michael CW
Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
[TBL] [Abstract][Full Text] [Related]
14. Detection of HEY1-NCOA2 fusion by fluorescence in-situ hybridization in formalin-fixed paraffin-embedded tissues as a possible diagnostic tool for mesenchymal chondrosarcoma.
Nakayama R; Miura Y; Ogino J; Susa M; Watanabe I; Horiuchi K; Anazawa U; Toyama Y; Morioka H; Mukai M; Hasegawa T
Pathol Int; 2012 Dec; 62(12):823-6. PubMed ID: 23252872
[TBL] [Abstract][Full Text] [Related]
15. NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
Huang H; Guma SR; Melamed J; Zhou M; Lee P; Deng FM
Am J Clin Exp Urol; 2018; 6(5):182-188. PubMed ID: 30510970
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic involvement by mesenchymal chondrosarcoma harboring the HEY1-NCOA2 gene fusion.
Cohen JN; Solomon DA; Horvai AE; Kakar S
Hum Pathol; 2016 Dec; 58():35-40. PubMed ID: 27544802
[TBL] [Abstract][Full Text] [Related]
17. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis.
Qi W; Rosikiewicz W; Yin Z; Xu B; Jiang H; Wan S; Fan Y; Wu G; Wang L
J Pathol; 2022 Aug; 257(5):579-592. PubMed ID: 35342947
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: a potential diagnostic pitfall.
Folpe AL; Graham RP; Martinez A; Schembri-Wismayer D; Boland J; Fritchie KJ
Hum Pathol; 2018 Jul; 77():28-34. PubMed ID: 29559236
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Takada N; Nishida H; Oyama Y; Kusaba T; Kadowaki H; Arakane M; Wada J; Urabe S; Daa T
Pathobiology; 2020; 87(1):30-36. PubMed ID: 31865345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
